托法替尼治疗巩膜炎：病例系列研究。
Tofacitinib in Scleritis: A Case Series.
机构信息
Department of Uvea, Medical and Vision Research Foundations, Sankara Nethralaya, Chennai, India.
Department of Rheumatology, Apollo Hospital, Chennai, India.
出版信息
Ocul Immunol Inflamm. 2024 Aug;32(6):884-890. doi: 10.1080/09273948.2022.2113805. Epub 2022 Sep 20.
PURPOSE
To report the use of tofacitinib in ten patients with scleritis where the traditional immunomodulation was not successful or could not be used.
METHOD
A retrospective chart review.
RESULT
Tofacitinib was successful in the treatment of scleritis in patients either recalcitrant to or intolerant to conventional therapy in 9 out of 10 cases reported here. Two patients had developed reactivation of herpetic infection after 1 month of starting tofacitinib. The duration from diagnosis of scleritis to the institution of tofacitinib therapy varied from 1 month to 60 months. Duration of follow-up varies from 2 months to 11 months.
CONCLUSION
Tofacitinib can be used as an important future option for managing recurrent and recalcitrant cases of scleritis.
目的
报告在传统免疫调节治疗无效或无法使用的情况下，使用托法替尼治疗 10 例巩膜炎患者的情况。
方法
回顾性病历分析。
结果
在报告的 10 例病例中，托法替尼成功治疗了 9 例对传统治疗有抗药性或不耐受的巩膜炎患者。有 2 例患者在开始使用托法替尼治疗 1 个月后出现疱疹感染复发。从巩膜炎诊断到开始使用托法替尼治疗的时间从 1 个月到 60 个月不等。随访时间从 2 个月到 11 个月不等。
结论
托法替尼可作为治疗复发性和难治性巩膜炎的重要选择。
Zotero 插件